MA-BATTERY-VENTURES
Battery Ventures, a global, technology-focused investment firm, announced the acquisition of Labguru (BioData Inc.), the life-science laboratory-data platform, from Holtzbrinck Digital. Terms were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417562351/en/
Labguru provides a comprehensive laboratory data-management hub for planning and tracking; documenting experiments; streamlining lab logistics; and sharing results across teams and organizations. Labguru’s easy-to-use, cloud-based, research-to-production life-science platform combines an Electronic Lab Notebook (ELN), a Laboratory Information Management System (LIMS) and a set of informatics tools to enable and enhance research and production. Labguru is trusted by hundreds of thousands of scientists across the biotechnology, pharmaceutical and advanced-industry segments, as well as researchers at global academic and research institutions.
Labguru will join Battery’s Titian Software to create a global organization that offers an end-to-end solution across life sciences and laboratory applications from research to production, spanning the entire workflow from ELN to inventory and sample management, research, testing and QC workflows.
“Together Titian and Labguru will use the investment by Battery to further support organic growth as well as shape the direction of the group’s future acquisitions, in fulfilling the group vision to become the one-stop shop of the global life-science software market,” said Battery General Partner Jesse Feldman.
“We are excited to bring together Titian and Labguru and to work with the companies’ leaders to provide an integrated laboratory and sample-management offering to researchers,” Feldman said. “The two companies already serve researchers across multiple disciplines at the forefront of science, and we look forward to expanding how we serve our customers.”
Labguru’s executive team, including CEO Ariel Yarnitsky and founder and CTO Jonathan Gross, will remain in their current roles, working alongside the Titian executive team following the transaction.
“We’re excited to join forces with Battery, a long-standing investor with domain expertise across life-science informatics and laboratory automation and leverage their vast experience during Labguru’s next growth phase,” said Yarnitsky. “Specifically, Labguru’s mission to build a leading solution catering to the broad needs of scientists in one coherent and easy-to-use platform becomes even more exciting by joining hands with Titian and with the strong support of Battery. Between the additional capital from Battery and the product and cultural fit with Titian, we could not think of a more suitable partner to propel Labguru forward.”
Founder Gross added: “Partnering with Battery and Titian will accelerate our ability to leverage technology, experience and insights to effectively widen the scope of our platform, benefiting science and scientists. This is an important and dramatic step in Labguru’s journey. Further, with Battery Ventures’ long-standing experience investing in data and AI companies, we have found a valuable partner to help shape our vision as we continue building on Labguru’s suite of artificial intelligence tools.”
Titian Software Founder and Chief Product Officer Edmund Wilson added, “We are delighted to partner with Labguru. Our companies share a common commitment to providing state-of-the-art solutions to the life sciences community, delivered by staff who offer tremendous domain expertise.”
Holtzbrinck Digital played a crucial role in Labguru's development and success. Their vision and support have been instrumental in the company's fast growth and positioning as a tier-1 lab-management software company. "We are extremely happy with Labguru's development over the last years and are proud of the strides we've made together. Finding a partner like Battery, who shares our commitment to innovation and excellence, marks a thrilling next chapter for Labguru," said Marc-Orell Dedorath, head of group M&A at Holtzbrinck.
“We are thrilled to unite two major forces in a market that's only beginning to realize its vast potential,” added Justin Rosner, a principal at Battery. “We look forward to working with the Labguru and Titian teams as we embark on this journey together."
About Labguru (BioData Inc.)
Labguru (BioData Inc.) was founded in 2007 and is the developer of a secure, cloud-based laboratory data management platform for life science research and industry. Labguru is an all-in-one platform that streamlines laboratory operations by recording and managing data and inventory, offering molecular biology and chemistry tools, enabling lab automation, and providing data-driven, AI-assisted insights for increased efficiency. As a trusted tool for more than 120,000 scientists worldwide, we empower the digitalization efforts of customers ranging from start-ups to global life science organizations. To learn more about Labguru, visit www.labguru.com.
About Titian Software
Titian Software was founded in 1999 and is a leading provider of sample management software solutions, catering to the unique needs of research laboratories, biobanks, and pharmaceutical companies worldwide. Titian's Mosaic Sample Management Software encompasses a comprehensive suite of tools for sample tracking, inventory management, and workflow automation. Mosaic empowers laboratories to efficiently manage vast repositories of samples, including compounds, biological materials, and clinical specimens while ensuring data integrity and traceability throughout the sample lifecycle. www.titian.co.uk.
About Battery Ventures
Battery partners with exceptional founders and management teams, developing category-defining businesses in markets including software and services, enterprise infrastructure, online marketplaces, healthcare IT, and industrial technology. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from six strategic locations: Boston; San Francisco and Menlo Park, Calif.; Tel Aviv; London; and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com, and find a complete list of Battery's portfolio companies here.
About Holtzbrinck Digital
Holtzbrinck Digital manages the investments of the Holtzbrinck Publishing Group in digital startups in the science and education sector, as well as other areas of strategic importance. Holtzbrinck Digital supports them in their development with expertise, resources, and a long-term commitment, enabling the companies to achieve the best possible development.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417562351/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom